Skip to content
20 November · 06:30 UTCFollow GSK by emailFollow

GSK · story · 20 November

Japan gives velzatinib orphan designation for GIST

GSK · 8 headlines from 7 outlets, on 20 November 2026.

The story

+5.8positive
Headlines8
Outlets7
Days120 November

Japan has given GSK's velzatinib orphan drug status for gastrointestinal stromal tumours, and pivotal data are expected in 2027.

The story's tone is the average of its headlines' own scores. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.

How each outlet covered it · 7 outlets

Every outlet, by impact on the tone

Average tone of each outlet's headlines in this story, −10 to +10. Impact = headlines × strength of tone.

Source: MarketFrame news analysis

Every outlet, by impact on the tone. Average tone of each outlet's headlines in this story, −10 to +10. Impact = headlines × strength of tone. Source: MarketFrame news analysis
outletAverage tone
TradingView5.8
Proactive Investors UK6.3
Moomoo5.8
Kalkine Media5.8
MarketScreener5.7
TipRanks5.7
Stock Titan5.5
OutletHeadlinesAverage tone
TradingView2+5.8
Proactive Investors UK1+6.3
Moomoo1+5.8
Kalkine Media1+5.8
MarketScreener1+5.7
TipRanks1+5.7
Stock Titan1+5.5

One or two headlines is not a lean: read these as how this story was told, not as a verdict on the outlet.

Day by day · 1 day, strongest headlines first

Friday 20 November 20268 headlines · Japan has given GSK's velzatinib orphan drug status for gastrointestinal stromal tumours, and pivotal data are expected in 2027.+5.8
ToneWhat the article reported, and why it scored that waySource
+6.3Designation plus a stated timeline for key trial data.Proactive Investors UK (opens the article) ↗
+5.8Company's own announcement of Japanese orphan status.TradingView (opens the article) ↗
+5.8Japanese special status for a cancer drug candidate aids development.Moomoo (opens the article) ↗
+5.8Rare-tumour drug receives favourable Japanese designation.Kalkine Media (opens the article) ↗
+5.7Orphan status in Japan supports the GIST candidate.MarketScreener (opens the article) ↗
+5.7Japanese orphan status granted for GIST treatment.TradingView (opens the article) ↗
+5.7Japanese orphan designation for gastrointestinal tumour drug.TipRanks (opens the article) ↗
+5.5Late-stage drug obtains rare-disease status in Japan.Stock Titan (opens the article) ↗

Follow by email

A short, free morning email on how the news treated GSK: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.

How it works. Every morning an AI model reads the UK business news about each FTSE 100 company and scores how good or bad it is for the company, from −10 to +10. Pages update by about 07:45 UK time.

Not investment advice. MarketFrame rates the tone of news coverage. It is general information, not a recommendation to buy or sell anything. The scores are not share-price data or forecasts: a good score doesn't mean a share will rise, and a bad one doesn't mean it will fall.

Data to 06:30 UTC, 20 November · 852 headlines · 87 companiesMade by Adapt Progress Evolve Limited, a UK company · Privacy · Terms · Who we are · RSS · API · llms.txt